Molecular pathways: Adipose inflammation as a mediator of obesity-associated cancer

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6074-6083

  Howe, Louise R ^a   Subbaramaiah, Kotha ^a   Hudis, Clifford A ^a,b   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADIPONECTIN; ANTIOBESITY AGENT; AROMATASE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ESTROGEN; ESTROGEN RECEPTOR; FETUIN; HORMONE RECEPTOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LORCASERIN; OMEGA 3 FATTY ACID; PHENTERMINE; PROSTAGLANDIN E2; SATURATED FATTY ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TETRAHYDROLIPSTATIN; TOLL LIKE RECEPTOR 4; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BARIATRIC SURGERY; BODY MASS; BREAST; BREAST CANCER; CALORIC RESTRICTION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL STRUCTURE; CLINICAL FEATURE; COX2 GENE; CYP19 GENE; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN SYNTHESIS; EXERCISE; FATTY ACID SYNTHESIS; GASTRIC BANDING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IL1 BETA GENE; IL6 GENE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIPOLYSIS; MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; OBESITY; OVARIECTOMY; PATIENT IDENTIFICATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RISK ASSESSMENT; ROUX Y ANASTOMOSIS; SEX DIFFERENCE; STOMACH BYPASS; SUBCUTANEOUS FAT; TNF ALPHA GENE; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOSE TISSUE; AROMATASE; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; NF-KAPPA B; OBESITY; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885392560     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2603     Document Type: Article

References (109)

1. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011;378:815-25.
2. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
3. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010;15:556-65.
4. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;137:307-14.
5. Iyengar NM, Morris PG, Hudis C, Dannenberg AJ. Obesity, inflammation, and breast cancer. In: Dannenberg AJ, Berger NA, eds. Obesity, inflammation and cancer. New York: Springer; 2013. p. 181-217.
6. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
7. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18:363-74.
8. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005;54:2277-86. (Pubitemid 41134253)
9. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-55. (Pubitemid 41532523)
10. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 2008;49:1562-8.
11. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011;4:1021-9.
12. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011;4:329-46.
13. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of cox-2 and prostaglandin e2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
14. Sun X, Casbas-Hernandez P, Bigelow C, Makowski L, Joseph Jerry D, Smith Schneider S, et al. Normal breast tissue of obese women is enrichedfor macrophagemarkers and macrophage-associated gene expression. Breast Cancer Res Treat 2012;131:1003-12.
15. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007;117:175-84. (Pubitemid 46048464)
16. Shapiro H, Pecht T, Shaco-Levy R, Harman-Boehm I, Kirshtein B, Kuperman Y, et al. Adipose tissue foam cells are present in human obesity. J Clin Endocrinol Metab 2013;98:1173-81.
17. Nicklas BJ, Rogus EM, Colman EG, Goldberg AP. Visceral adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women. Am J Physiol 1996;270:E72-8.
18. Lee JY, Ye J, Gao Z, Youn HS, Lee WH, Zhao L, et al. Reciprocal modulation of toll-like receptor-4 signaling pathways involving myd88 and phosphatidylinositol 3-kinase/akt by saturated and polyunsaturated fatty acids. J Biol Chem 2003;278:37041-51. (Pubitemid 37175218)
19. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. Tlr4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-25. (Pubitemid 44684486)
20. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin- A acts as an endogenous ligand of tlr4 to promote lipidinduced insulin resistance. Nat Med 2012;18:1279-85.
21. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292:G518-25.
22. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761-72. (Pubitemid 47025442)
23. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
24. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
25. Cavalieri EL, Rogan EG. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 2011;125:169-80.
26. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, et al. Aromatase- A brief overview. Annu Rev Physiol 2002;64:93-127.
27. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome p450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622-8. (Pubitemid 24000924)
28. Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews YL. Prognostic value of breast cancer aromatase. Cancer 1992;70:1951-5.
29. Miller WR, Anderson TJ, Jack WJ. Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 1990;37:1055-9.
30. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I, et al. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989;49:2588-91. (Pubitemid 19143382)
31. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31. (Pubitemid 19148455)
32. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int J Epidemiol 1991;20:151-6.
33. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003;21:1961-6. (Pubitemid 46606384)
34. Brueggemeier RW, Richards JA, Joomprabutra S, Bhat AS, Whetstone JL. Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. J Steroid Biochem Mol Biol 2001;79:75-84. (Pubitemid 34158781)
35. Singh A, Purohit A, Ghilchik MW, Reed MJ. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin e2. Endocr Relat Cancer 1999;6:139-47. (Pubitemid 29260045)
36. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by pge2 via cyclic amp, leading to activation of promoter ii of the cyp19 (aromatase) gene. Endocrinology 1996;137:5739-42. (Pubitemid 26423150)
37. Subbaramaiah K, Hudis C, Chang SH, Hla T, Dannenberg AJ. Ep2 and ep4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a brca1 and p300 exchange. J Biol Chem 2008;283:3433-44.
38. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of p450 cyp19 aromatase promoter regions pii, pi.3 and pi.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 2006;81:55-70. (Pubitemid 44403171)
39. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9. (Pubitemid 34248122)
40. Samarajeewa NU, Yang F, Docanto MM, Sakurai M, McNamara KM, Sasano H, et al. Hif-1alpha stimulates aromatase expression driven by prostaglandin e2 in breast adipose stroma. Breast Cancer Res 2013;15:R30.
41. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome p450 (cyp19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996;81:3843-9. (Pubitemid 26380384)
42. Chen S, Itoh T, Wu K, Zhou D, Yang C. Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol 2002;83:93-9. (Pubitemid 37040645)
43. Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome p450 gene expression in human adipose tissue. J Biol Chem 1993;268:19463-70. (Pubitemid 23270727)
44. Zhou D, Chen S. Identification and characterization of a campresponsive element in the region upstream from promoter 1.3 of the human aromatase gene. Arch Biochem Biophys 1999;371:179-90.
45. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, et al. Aromatase and cox-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-7. (Pubitemid 34158777)
46. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35. (Pubitemid 29251310)
47. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG, Mokbel K. Cyclooxygenase-2 mrna expression correlates with aromatase expression in human breast cancer. J Surg Oncol 2007;96:424-8. (Pubitemid 47519449)
48. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, et al. Her-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006;66:5504-11. (Pubitemid 43844979)
49. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226. (Pubitemid 29473315)
50. Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet 2001;357:539-45. (Pubitemid 32173595)
51. Howe LR. Pharmacologic interventions with NSAIDs. In: Dannenberg AJ, Berger NA, eds. Obesity, inflammation and cancer. New York: Springer; 2013. p. 257-303.
52. Howe LR, Subbaramaiah K, Brown A M C, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114. (Pubitemid 32641352)
53. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
54. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci 2012;1271:82-7.
55. Cleary MP, Grossmann ME, Ray A. Effect of obesity on breast cancer development. Vet Pathol 2010;47:202-13.
56. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormonerefractory metastatic breast cancer patients. Br J Cancer 2003;88:1721-6. (Pubitemid 36760416)
57. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998;83:2907-10. (Pubitemid 28493796)
58. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001;9:414-7. (Pubitemid 33603868)
59. Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, et al. Hyperinsulinemia promotes metastasis to the lung in a mouse model of her2-mediated breast cancer. Endocr Relat Cancer 2013;20:391-401.
60. Clement K, Viguerie N, Poitou C, Carette C, Pelloux V, Curat CA, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004;18:1657-69. (Pubitemid 39463705)
61. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the women's intervention nutrition study. J Natl Cancer Inst 2006;98:1767-76. (Pubitemid 46017928)
62. Bhardwaj P, Du B, Zhou XK, Sue E, Harbus MD, Falcone DJ, et al. Caloric restriction reverses obesity-induced mammary gland inflammation in mice. Cancer Prev Res (Phila) 2013;6:282-9.
63. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-42.
64. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, et al. Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial. J Clin Oncol 2012;30:2314-26.
65. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804. (Pubitemid 37430249)
66. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 2012;72:2314-26.
67. van Rossum EF, Nicklas BJ, Dennis KE, Berman DM, Goldberg AP. Leptin responses to weight loss in postmenopausal women: relationship to sex-hormone binding globulin and visceral obesity. Obes Res 2000;8:29-35.
68. Ligibel JA, Goodwin PJ. New and renew: building the case for weight loss in breast cancer. J Clin Oncol 2012;30:2294-6.
69. Ahn SM, Pomp A, Rubino F. Metabolic surgery for type 2 diabetes. Ann N Y Acad Sci 2010;1212:E37-45.
70. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248-56.e5.
71. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009;17:796-802.
72. Sjostrom L. Review of the key results from the swedish obese subjects (sos) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219-34.
73. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell 2013;152:673-84.
74. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 2013;110:9066-71.
75. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The tlr4 antagonist eritoran protects mice from lethal influenza infection. Nature 2013;497:498-502.
76. Siriwardhana N, Kalupahana NS, Cekanova M, Lemieux M, Greer B, Moustaid-Moussa N. Modulation of adipose tissue inflammation by bioactive food compounds. J Nutr Biochem 2013;24:613-23.
77. Kalupahana NS, Claycombe K, Newman SJ, Stewart T, Siriwardhana N, Matthan N, et al. Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr 2010;140:1915-22.
78. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 2006;49:2109-19. (Pubitemid 44168479)
79. Signori C, El-BayoumyK, Russo J, Thompson HJ, Richie JP, Hartman TJ, et al. Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Res 2011;71:6091-6.
80. Chajes V, Torres-Mejia G, Biessy C, Ortega-Olvera C, Angeles-Llerenas A, Ferrari P, et al. Omega-3 and omega-6 polyunsaturated fatty acid intakes and the risk of breast cancer in mexican women: impact of obesity status. Cancer Epidemiol Biomarkers Prev 2012;21:319-26.
81. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 2010;31:83-9.
82. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev 2012;11:390-8.
83. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 2011;81:1343-51.
84. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of nf-{kappa}b is controlled by mtor and raptor in association with ikk. Genes Dev 2008;22:1490-500. (Pubitemid 351793083)
85. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012;48:R31-43.
86. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012;2:778-90.
87. Boyle JG, Logan PJ, Jones GC, Small M, Sattar N, Connell JM, et al. Amp-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 2011;54:1799-809.
88. Salminen A, Hyttinen JM, Kaarniranta K. Amp-activated protein kinase inhibits nf-kappab signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011;89:667-76.
89. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of amp-activated protein kinase. Breast Cancer Res Treat 2010;123:591-6.
90. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2012;5:164-78.
91. Kopp E, Ghosh S. Inhibition of nf-kappa b by sodium salicylate and aspirin. Science 1994;265:956-9.
92. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of nf-kappab activation. Science 1996;274:1383-5. (Pubitemid 26391464)
93. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the nf-kappab pathway. J Biol Chem 1999;274:27307-14.
94. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of i (kappa) b kinase-beta. Nature 1998;396:77-80. (Pubitemid 28520452)
95. Din FV, Stark LA, Dunlop MG. Aspirin-induced nuclear translocation of nfkappab and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br J Cancer 2005;92:1137-43. (Pubitemid 40546681)
96. Loveridge CJ, MacDonald AD, Thoms HC, Dunlop MG, Stark LA. The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the rela (p65) subunit of nfkappab. Oncogene 2008;27:2648-55. (Pubitemid 351550873)
97. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates amp-activated protein kinase. Science 2012;336:918-22.
98. Din FV, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, et al. Aspirin inhibits mtor signaling, activates amp-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012;142:1504-15.e3.
99. Hudis CA, Subbaramaiah K, Morris PG, Dannenberg AJ. Breast cancer risk reduction: no pain, no gain? J Clin Oncol 2012;30:3436-8.
100. Zhang X, Smith-Warner SA, Chan AT, Wu K, Spiegelman D, Fuchs CS, et al. Aspirin use, body mass index, physical activity, plasma c-peptide, and colon cancer risk in US health professionals. Am J Epidemiol 2011;174:459-67.
101. Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, et al. Aspirin may be more effective in preventing colorectal adenomas in patients with higher bmi (united states). Cancer Causes Control 2006;17:1299-304. (Pubitemid 44772831)
102. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:1033-41.
103. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, et al. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:680-7. (Pubitemid 351469220)
104. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, et al. Targeting the ikkbeta/mtor/vegf signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther 2012;11:2212-21.
105. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 2010;28:3411-5.
106. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, et al. Quantification of the major urinary metabolite of pge2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase- specific pge2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004;334:266-75. (Pubitemid 39370961)
107. Kim S, Taylor JA, Milne GL, Sandler DP. Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila) 2013;6:511-8.
108. Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, et al. Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) 2013;6:428-36.
109. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.